Pacific Biosciences of California Stock Price, News & Analysis (NASDAQ:PACB)

$2.74 -0.03 (-1.08 %)
(As of 12/13/2017 04:00 PM ET)
Previous Close$2.77
Today's Range$2.72 - $2.85
52-Week Range$2.66 - $7.00
Volume595,647 shs
Average Volume1.09 million shs
Market Capitalization$318.52 million
P/E RatioN/A
Dividend YieldN/A
Beta1.75

About Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California logoPacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.

Receive PACB News and Ratings via Email

Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:PACB
CUSIP69404D10
Phone650-521-8000

Debt

Debt-to-Equity Ratio0.10%
Current Ratio3.75%
Quick Ratio3.15%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$90.71 million
Price / Sales3.51
Cash FlowN/A
Price / CashN/A
Book Value$0.91 per share
Price / Book3.01

Profitability

Trailing EPS($0.92)
Net Income$-74,370,000.00
Net Margins-95.97%
Return on Equity-97.50%
Return on Assets-59.40%

Miscellaneous

Employees438
Outstanding Shares116,250,000

Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California (NASDAQ:PACB) released its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.01. The biotechnology company had revenue of $23.54 million for the quarter, compared to analyst estimates of $28.29 million. Pacific Biosciences of California had a negative net margin of 95.97% and a negative return on equity of 97.50%. The company's quarterly revenue was down 6.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.19) earnings per share. View Pacific Biosciences of California's Earnings History.

When will Pacific Biosciences of California make its next earnings announcement?

Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Wednesday, January, 31st 2018. View Earnings Estimates for Pacific Biosciences of California.

Where is Pacific Biosciences of California's stock going? Where will Pacific Biosciences of California's stock price be in 2017?

3 analysts have issued 12-month target prices for Pacific Biosciences of California's shares. Their predictions range from $4.00 to $8.00. On average, they expect Pacific Biosciences of California's share price to reach $6.27 in the next year. View Analyst Ratings for Pacific Biosciences of California.

What are Wall Street analysts saying about Pacific Biosciences of California stock?

Here are some recent quotes from research analysts about Pacific Biosciences of California stock:

  • 1. According to Zacks Investment Research, "Pacific Biosciences posted narrower-than-expected loss in the third quarter. Solid contribution from the Instrument and Consumable revenue platforms has been boosting the company’s growth trajectory. The improvement in margin and sales of the company’s flagship Sequel System is encouraging. Pacific Biosciences has been witnessing significant strength in China lately. Notably, it placed numerous system orders in the region. The company is working on the new version of its Sequel SMRT Cell (Single Molecule, Real-Time) that has eight times the capacity of the existing one. On the flipside, sluggishness in European markets is a headwind. Cutthroat competition in the niche space is an added concern. Problems related to the limited availability of SMRT cells for the Sequel system and higher non-cash operating expenses are expected to mar prospects. Pacific Biosciences has had an unfavorable run on the bourses over the last six months." (11/9/2017)
  • 2. Cantor Fitzgerald analysts commented, "Solid 4Q16 results despite lower than-expected Sequel bookings. The company reported total revenues of $25.7M, $2.5M above our estimate of $23.2M and $2.7M above FactSet consensus of $23.0M. System revenue beat due to strong placements in the quarter, slightly offset by lower-than-expected consumable revenue." (2/3/2017)

Who are some of Pacific Biosciences of California's key competitors?

Who are Pacific Biosciences of California's key executives?

Pacific Biosciences of California's management team includes the folowing people:

  • Michael W. Hunkapiller Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 68)
  • Susan K. Barnes, Chief Financial Officer, Executive Vice President, Principal Accounting Officer (Age 63)
  • Kathy P. Ordonez, Executive Vice President and Chief Commercial Officer and Director (Age 66)
  • Kevin P. Corcoran, Senior Vice President - Market Development (Age 58)
  • James Michael Phillips, Senior Vice President - Research and Development (Age 66)
  • William W. Ericson, Lead Independent Director (Age 58)
  • David Botstein Ph.D., Independent Director (Age 72)
  • Brook H. Byers Ph.D., Independent Director (Age 71)
  • Randall S. Livingston, Independent Director (Age 63)
  • John F. Milligan Ph.D., Independent Director (Age 55)

Who owns Pacific Biosciences of California stock?

Pacific Biosciences of California's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Frontier Capital Management Co. LLC (1.29%), Mutual of America Capital Management LLC (0.42%), Bank of New York Mellon Corp (0.40%), Schwab Charles Investment Management Inc. (0.35%), Aperio Group LLC (0.04%) and Gilder Gagnon Howe & Co. LLC (0.02%). View Institutional Ownership Trends for Pacific Biosciences of California.

Who sold Pacific Biosciences of California stock? Who is selling Pacific Biosciences of California stock?

Pacific Biosciences of California's stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC and Frontier Capital Management Co. LLC. View Insider Buying and Selling for Pacific Biosciences of California.

Who bought Pacific Biosciences of California stock? Who is buying Pacific Biosciences of California stock?

Pacific Biosciences of California's stock was acquired by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Bank of New York Mellon Corp, Aperio Group LLC and Mutual of America Capital Management LLC. View Insider Buying and Selling for Pacific Biosciences of California.

How do I buy Pacific Biosciences of California stock?

Shares of Pacific Biosciences of California can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacific Biosciences of California's stock price today?

One share of Pacific Biosciences of California stock can currently be purchased for approximately $2.74.

How big of a company is Pacific Biosciences of California?

Pacific Biosciences of California has a market capitalization of $318.52 million and generates $90.71 million in revenue each year. The biotechnology company earns $-74,370,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. Pacific Biosciences of California employs 438 workers across the globe.

How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]


MarketBeat Community Rating for Pacific Biosciences of California (PACB)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  167 (Vote Underperform)
Total Votes:  331
MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pacific Biosciences of California (NASDAQ:PACB) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.252.252.602.57
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.70$7.70$11.70$11.58
Price Target Upside: 91.07% upside91.07% upside125.87% upside123.62% upside

Pacific Biosciences of California (NASDAQ:PACB) Consensus Price Target History

Price Target History for Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California (NASDAQ:PACB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/3/2017First AnalysisDowngradeOverweight -> Equal Weight$4.00N/AView Rating Details
9/28/2017CL KingDowngradeBuy -> Neutral$6.80HighView Rating Details
4/27/2017Cantor FitzgeraldSet Price TargetBuy$8.00MediumView Rating Details
11/3/2016J P Morgan Chase & CoReiterated RatingHold$12.00N/AView Rating Details
4/15/2016MKM PartnersInitiated CoverageNeutral$16.50N/AView Rating Details
2/5/2016StephensReiterated RatingBuyN/AView Rating Details
2/4/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$9.00 -> $11.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Pacific Biosciences of California (NASDAQ:PACB) Earnings History and Estimates Chart

Earnings by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California (NASDAQ PACB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/31/2018N/AView Earnings Details
11/2/2017Q3 2017($0.20)($0.19)$28.29 million$23.54 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.24)($0.26)$23.34 million$20.07 millionViewListenView Earnings Details
4/26/2017Q1 2017($0.23)($0.26)$23.80 million$24.90 millionViewN/AView Earnings Details
2/2/2017Q416($0.23)($0.21)$22.84 million$25.70 millionViewListenView Earnings Details
11/2/2016Q316($0.20)($0.19)$24.68 million$25.10 millionViewN/AView Earnings Details
8/4/2016Q2($0.22)($0.21)$20.19 million$20.70 millionViewN/AView Earnings Details
4/21/2016Q1($0.25)($0.23)$18.02 million$19.10 millionViewListenView Earnings Details
2/3/2016Q4($0.02)($0.02)$36.96 million$36.28 millionViewN/AView Earnings Details
10/22/2015Q3($0.27)$0.02$15.84 million$13.90 millionViewListenView Earnings Details
8/5/2015Q215($0.14)($0.16)$26.36 million$24.94 millionViewListenView Earnings Details
5/5/2015Q115($0.27)($0.27)$13.70 million$17.65 millionViewN/AView Earnings Details
2/3/2015Q414($0.26)($0.26)$14.90 million$16.90 millionViewListenView Earnings Details
10/23/2014Q214($0.16)($0.13)$17.20 million$20.60 millionViewListenView Earnings Details
7/24/2014Q114($0.15)($0.27)$11.39 million$11.40 millionViewN/AView Earnings Details
4/30/2014($0.28)($0.28)$10.17 million$11.64 millionViewN/AView Earnings Details
2/4/2014Q413($0.27)($0.26)$9.13 million$9.10 millionViewN/AView Earnings Details
10/22/2013Q313($0.30)($0.31)$7.08 million$7.40 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.35)($0.33)$6.09 million$6.04 millionViewN/AView Earnings Details
4/23/2013Q1 2013($0.37)($0.37)$4.28 million$5.60 millionViewN/AView Earnings Details
2/5/2013Q4 2012($0.37)($0.39)$4.38 million$5.90 millionViewN/AView Earnings Details
10/25/2012($0.45)($0.41)ViewN/AView Earnings Details
7/26/2012($0.46)($0.40)ViewN/AView Earnings Details
5/1/2012($0.47)($0.50)ViewN/AView Earnings Details
2/7/2012($0.50)($0.42)ViewN/AView Earnings Details
8/4/2011($0.63)($0.42)ViewN/AView Earnings Details
4/27/2011($0.67)($0.66)ViewN/AView Earnings Details
2/15/2011($0.91)($0.97)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Pacific Biosciences of California (NASDAQ:PACB) Earnings Estimates

2017 EPS Consensus Estimate: ($0.84)
2018 EPS Consensus Estimate: ($0.64)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.21)($0.19)($0.20)
Q2 20172($0.26)($0.24)($0.25)
Q3 20172($0.23)($0.18)($0.21)
Q4 20172($0.19)($0.17)($0.18)
Q1 20182($0.19)($0.16)($0.18)
Q2 20182($0.18)($0.16)($0.17)
Q3 20182($0.17)($0.14)($0.16)
Q4 20181($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Pacific Biosciences of California (NASDAQ:PACB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Pacific Biosciences of California (NASDAQ PACB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 17.80%
Institutional Ownership Percentage: 70.51%
Insider Trades by Quarter for Pacific Biosciences of California (NASDAQ:PACB)
Institutional Ownership by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California (NASDAQ PACB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/28/2016James Michael PhillipsSVPSell20,000$8.44$168,800.00View SEC Filing  
7/29/2016James Michael PhillipsSVPSell20,000$8.45$169,000.00View SEC Filing  
4/25/2016James Michael PhillipsSVPSell20,000$10.29$205,800.00View SEC Filing  
3/2/2015Brian B DowVPBuy2,503$4.91$12,289.73View SEC Filing  
3/2/2015Kevin P CorcoranSVPBuy2,816$4.91$13,826.56View SEC Filing  
8/19/2014William W EricsonDirectorBuy39,299$5.14$201,996.86View SEC Filing  
8/18/2014William W EricsonDirectorBuy135,155$5.09$687,938.95View SEC Filing  
8/14/2014William W EricsonDirectorBuy77,822$5.00$389,110.00View SEC Filing  
8/13/2014William W EricsonDirectorBuy29,435$4.93$145,114.55View SEC Filing  
8/12/2014William W EricsonDirectorBuy123,423$4.89$603,538.47View SEC Filing  
12/12/2013Michael HunkapillerCEOBuy100,000$4.13$413,000.00View SEC Filing  
11/21/2013Michael HunkapillerCEOBuy200,000$3.61$722,000.00View SEC Filing  
12/3/2012Michael HunkapillerCEOBuy154,100$1.75$269,675.00View SEC Filing  
11/29/2012Michael HunkapillerCEOBuy242,200$1.68$406,896.00View SEC Filing  
11/26/2012Michael HunkapillerCEOBuy186,400$1.44$268,416.00View SEC Filing  
11/20/2012Michael HunkapillerCEOBuy155,000$1.27$196,850.00View SEC Filing  
11/16/2012Michael HunkapillerCEOBuy262,300$1.16$304,268.00View SEC Filing  
8/7/2012Michael HunkapillerCEOBuy400,000$1.75$700,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pacific Biosciences of California (NASDAQ PACB) News Headlines

Source:
DateHeadline
Pacific Biosciences of California (PACB) Given Consensus Recommendation of "Hold" by AnalystsPacific Biosciences of California (PACB) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 12 at 1:56 AM
Head to Head Comparison: Accuray (ARAY) vs. Pacific Biosciences of California (PACB)Head to Head Comparison: Accuray (ARAY) vs. Pacific Biosciences of California (PACB)
www.americanbankingnews.com - December 4 at 12:02 PM
Pacific Biosciences of California (PACB) Expected to Post Quarterly Sales of $21.69 MillionPacific Biosciences of California (PACB) Expected to Post Quarterly Sales of $21.69 Million
www.americanbankingnews.com - November 29 at 11:24 AM
Zacks: Brokerages Expect Pacific Biosciences of California (PACB) to Announce -$0.19 Earnings Per ShareZacks: Brokerages Expect Pacific Biosciences of California (PACB) to Announce -$0.19 Earnings Per Share
www.americanbankingnews.com - November 27 at 3:16 AM
ETFs with exposure to Pacific Biosciences of California, Inc. : November 20, 2017ETFs with exposure to Pacific Biosciences of California, Inc. : November 20, 2017
finance.yahoo.com - November 21 at 9:08 AM
PacBio And GENEWIZ Announce Winner Of The 2017 AACR SMRT GrantPacBio And GENEWIZ Announce Winner Of The 2017 AACR SMRT Grant
finance.yahoo.com - November 18 at 10:46 AM
Pacific Biosciences of California, Inc. (PACB) Given Average Recommendation of "Hold" by BrokeragesPacific Biosciences of California, Inc. (PACB) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 17 at 1:48 AM
FY2017 Earnings Estimate for Pacific Biosciences of California, Inc. (PACB) Issued By William BlairFY2017 Earnings Estimate for Pacific Biosciences of California, Inc. (PACB) Issued By William Blair
www.americanbankingnews.com - November 10 at 1:58 PM
Zacks: Analysts Expect Pacific Biosciences of California, Inc. (PACB) Will Post Quarterly Sales of $26.67 MillionZacks: Analysts Expect Pacific Biosciences of California, Inc. (PACB) Will Post Quarterly Sales of $26.67 Million
www.americanbankingnews.com - November 10 at 4:51 AM
Pacific Biosciences of California, Inc. (PACB) Stock Rating Upgraded by Zacks Investment ResearchPacific Biosciences of California, Inc. (PACB) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 9 at 1:00 PM
ETFs with exposure to Pacific Biosciences of California, Inc. : November 8, 2017ETFs with exposure to Pacific Biosciences of California, Inc. : November 8, 2017
finance.yahoo.com - November 9 at 11:02 AM
Zacks: Analysts Anticipate Pacific Biosciences of California, Inc. (PACB) to Post -$0.19 Earnings Per ShareZacks: Analysts Anticipate Pacific Biosciences of California, Inc. (PACB) to Post -$0.19 Earnings Per Share
www.americanbankingnews.com - November 8 at 2:32 PM
Pacific Biosciences of California, Inc. :PACB-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Pacific Biosciences of California, Inc. :PACB-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 8:27 AM
First Analysis Weighs in on Pacific Biosciences of California, Inc.s Q3 2018 Earnings (PACB)First Analysis Weighs in on Pacific Biosciences of California, Inc.'s Q3 2018 Earnings (PACB)
www.americanbankingnews.com - November 6 at 12:32 PM
Pacific Biosciences of California, Inc. (PACB) Downgraded by First Analysis to Equal WeightPacific Biosciences of California, Inc. (PACB) Downgraded by First Analysis to Equal Weight
www.americanbankingnews.com - November 5 at 8:57 PM
BRIEF-Pacific Biosciences Of California reports Q3 revenue $23.5 mlnBRIEF-Pacific Biosciences Of California reports Q3 revenue $23.5 mln
www.reuters.com - November 4 at 4:23 PM
Pacific Biosciences Appoints Kathy Ordonez As Chief Commercial OfficerPacific Biosciences Appoints Kathy Ordonez As Chief Commercial Officer
www.thestreet.com - November 4 at 4:23 PM
Pacific Biosciences Appoints Kathy Ordoñez as Chief Commercial OfficerPacific Biosciences Appoints Kathy Ordoñez as Chief Commercial Officer
finance.yahoo.com - November 4 at 4:23 PM
Pacific Biosciences reports 3Q lossPacific Biosciences reports 3Q loss
finance.yahoo.com - November 4 at 4:23 PM
Edited Transcript of PACB earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of PACB earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 4 at 4:23 PM
Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech MoversPacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers
finance.yahoo.com - November 4 at 4:22 PM
Pacific Biosciences (PACB) Q3 Loss Narrower Than EstimatedPacific Biosciences (PACB) Q3 Loss Narrower Than Estimated
finance.yahoo.com - November 4 at 4:22 PM
Here's Why Pacific Biosciences of California Is Getting Hammered TodayHere's Why Pacific Biosciences of California Is Getting Hammered Today
finance.yahoo.com - November 4 at 4:22 PM
Pacific Biosciences Appoints Kathy Ordoñez as Chief Commercial Officer - GlobeNewswire (press release)Pacific Biosciences Appoints Kathy Ordoñez as Chief Commercial Officer - GlobeNewswire (press release)
www.globenewswire.com - November 4 at 8:37 AM
Pacific Biosciences (PACB) Q3 Loss Narrower Than Estimated - NasdaqPacific Biosciences (PACB) Q3 Loss Narrower Than Estimated - Nasdaq
www.nasdaq.com - November 4 at 8:37 AM
Pacific Biosciences of Californias (PACB) CEO Mike Hunkapiller on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaPacific Biosciences of California's (PACB) CEO Mike Hunkapiller on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 4 at 8:37 AM
Pacific Biosciences of California, Inc. (PACB) Announces Quarterly  Earnings Results, Beats Estimates By $0.01 EPSPacific Biosciences of California, Inc. (PACB) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - November 3 at 7:02 PM
Heres Why Pacific Biosciences of California Is Getting Hammered TodayHere's Why Pacific Biosciences of California Is Getting Hammered Today
www.fool.com - November 3 at 1:53 PM
Pacific Biosciences of California Posts Big Third Quarter LossPacific Biosciences of California Posts Big Third Quarter Loss
www.fool.com - November 3 at 10:26 AM
Analyzing Pacific Biosciences of California (PACB) & Dynatronics Corporation (DYNT)Analyzing Pacific Biosciences of California (PACB) & Dynatronics Corporation (DYNT)
www.americanbankingnews.com - November 1 at 5:06 AM
ETFs with exposure to Pacific Biosciences of California, Inc. : October 27, 2017ETFs with exposure to Pacific Biosciences of California, Inc. : October 27, 2017
finance.yahoo.com - October 28 at 12:17 PM
Pacific Biosciences of California, Inc. (PACB) Set to Announce Quarterly Earnings on TuesdayPacific Biosciences of California, Inc. (PACB) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 24 at 6:40 AM
Pacific Biosciences of California, Inc. (PACB) Receives Consensus Rating of "Hold" from AnalystsPacific Biosciences of California, Inc. (PACB) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - October 23 at 2:06 AM
$28.49 Million in Sales Expected for Pacific Biosciences of California, Inc. (PACB) This Quarter$28.49 Million in Sales Expected for Pacific Biosciences of California, Inc. (PACB) This Quarter
www.americanbankingnews.com - October 21 at 1:52 AM
Head-To-Head Survey: Digirad Corporation (DRAD) vs. Pacific Biosciences of California (PACB)Head-To-Head Survey: Digirad Corporation (DRAD) vs. Pacific Biosciences of California (PACB)
www.americanbankingnews.com - October 20 at 12:22 PM
Recent Projects Highlight Success of SMRT Sequencing for Characterizing Structural Variation in Human Genomes - GlobeNewswire (press release)Recent Projects Highlight Success of SMRT Sequencing for Characterizing Structural Variation in Human Genomes - GlobeNewswire (press release)
globenewswire.com - October 17 at 3:49 PM
ETFs with exposure to Pacific Biosciences of California, Inc. : October 17, 2017ETFs with exposure to Pacific Biosciences of California, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 3:49 PM
Recent Projects Highlight Success of SMRT Sequencing for Characterizing Structural Variation in Human GenomesRecent Projects Highlight Success of SMRT Sequencing for Characterizing Structural Variation in Human Genomes
finance.yahoo.com - October 17 at 6:08 AM
Pacific Biosciences of California, Inc. breached its 50 day moving average in a Bearish Manner : PACB-US : October 11, 2017Pacific Biosciences of California, Inc. breached its 50 day moving average in a Bearish Manner : PACB-US : October 11, 2017
finance.yahoo.com - October 12 at 8:00 AM
Reviewing Pacific Biosciences of California (PACB) & Its CompetitorsReviewing Pacific Biosciences of California (PACB) & Its Competitors
www.americanbankingnews.com - October 10 at 2:14 PM
Pacific Biosciences of California, Inc. :PACB-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017Pacific Biosciences of California, Inc. :PACB-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
finance.yahoo.com - October 5 at 2:52 PM
ETFs with exposure to Pacific Biosciences of California, Inc. : October 5, 2017ETFs with exposure to Pacific Biosciences of California, Inc. : October 5, 2017
finance.yahoo.com - October 5 at 2:52 PM
Head to Head Contrast: Mindray Medical International (MR) & Pacific Biosciences of California (PACB)Head to Head Contrast: Mindray Medical International (MR) & Pacific Biosciences of California (PACB)
www.americanbankingnews.com - October 2 at 6:28 AM
 Brokerages Anticipate Pacific Biosciences of California, Inc. (PACB) Will Announce Quarterly Sales of $28.49 Million Brokerages Anticipate Pacific Biosciences of California, Inc. (PACB) Will Announce Quarterly Sales of $28.49 Million
www.americanbankingnews.com - October 2 at 2:58 AM
Pacific Biosciences of California, Inc. (PACB) Cut to "Neutral" at CL KingPacific Biosciences of California, Inc. (PACB) Cut to "Neutral" at CL King
www.americanbankingnews.com - September 28 at 8:20 PM
Pacific Biosciences of California, Inc. (PACB) Given Average Recommendation of "Hold" by AnalystsPacific Biosciences of California, Inc. (PACB) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 28 at 9:38 AM
Next-Generation Sequencing Market by Product, Services, & Application - Global Forecasts to 2022Next-Generation Sequencing Market by Product, Services, & Application - Global Forecasts to 2022
www.prnewswire.com - September 14 at 8:55 AM
Critical Review: Pacific Biosciences of California (PACB) and its RivalsCritical Review: Pacific Biosciences of California (PACB) and its Rivals
www.americanbankingnews.com - September 12 at 11:00 AM
 Brokerages Anticipate Pacific Biosciences of California, Inc. (PACB) to Announce -$0.20 Earnings Per Share Brokerages Anticipate Pacific Biosciences of California, Inc. (PACB) to Announce -$0.20 Earnings Per Share
www.americanbankingnews.com - September 12 at 6:34 AM
Pacific Biosciences of California (PACB) Presents At Photonics Summit and Workshop - SlideshowPacific Biosciences of California (PACB) Presents At Photonics Summit and Workshop - Slideshow
seekingalpha.com - September 7 at 7:24 AM

SEC Filings

Pacific Biosciences of California (NASDAQ:PACB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pacific Biosciences of California (NASDAQ:PACB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pacific Biosciences of California (NASDAQ PACB) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.